Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Contact information


http://www.cebm.ox.ac.uk

 

DPhil Students: Carl supervises a diverse range of students  in the field of evidence-based medicine. 

See examples of completed supervised thesis at the ORA.

Websites

  • CEBM

    The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare.

  • MSc in EBHC

    Training and nurturing the next generation of global leaders in evidence, across a diverse range of qualifications, to inform better health care.

  • Global Centre for Healthcare and Urbanisation

    seeks to make urban centres environmentally, economically, and socially sustainable, and to provide an environment that supports and sustains health and wellbeing.

  • Trust the Evidence

    Discussing the latest research evidence to inform healthcare decisions

Carl Heneghan

BM, BCH, MA, MRCGP, DPhil

Professor of Evidence-Based Medicine

  • Director of CEBM & Programs in EBHC
  • NHS Urgent Care GP
  • Co-Director Global Centre for Healthcare & Urbanisation

Carl Heneghan is a clinical epidemiologist with expertise in evidence-based medicine, research methods, and evidence synthesis. 

With a wealth of experience, Carl Heneghan has authored over 450 peer-reviewed publications (current H index 99) and published over 110 systematic reviews, demonstrating his deep understanding of the field. 

His work includes investigating the evidence for approval of drugs and devices, assessing health claims and researching common presenting conditions in the community.

He has investigated antivirals, including Tamiflu, acute respiratory infections, and the transmission of SARs-CoV-2. He is also an expert in medical device regulation, diagnosis and screening, and avoidable le harms.

Carl Heneghan's impactful projects, such as the COVID-19 Evidence Service,  anticoagulation care, Primodos & congenital malformations, the harms of transvaginal mesh, and the transmission of SARs-CoV-2 (see CEBM research), serve as a testament to his significant contributions to the field.

He is a clinical advisor to two UK All Parliamentary Party Groups, an adviser to the WHO clinical trials registry platform, and a founder of the AllTrials campaign. The HSJ twice named him one of the top 100 NHS clinical leaders. In 2018, he received NIHR Senior Investigator status.

Teaching:

In 2019, Carl Heneghan's dedication to education and teaching was recognized​​ with a lifetime achievement award from Oxford's Medical Science Division. As the Director of the Centre for Evidence-Based Medicine (CEBM), he continues to build capacity through teaching and training activities, inspiring undergraduates, postgraduates, and teachers at EBM and is the field of programs in EBHC.

Dissemination and Media:

He writes regularly at Trust the Evidence and in the media (e.g., The Spectator).See expert page

Global Centre for Healthcare and Urbanisation (GCHU)

He is co-director of the GCHU based at Kellogg College, which was established to foster a better understanding of the interaction between healthcare and urbanisation. 

OUGC:

He is the President/Senior Member of the Oxford University Golf Club

Conflicts of interest and payments:

He holds grant funding from the NIHR and previously from the WHO for a series of ongoing Living rapid reviews on the modes of transmission of SARs-CoV-2 reference WHO registration 2020/1077093. He has received financial remuneration from an asbestos case and given legal advice on mesh, hormone pregnancy tests and sodium valproate. He receives expenses and payments for his media work and teaching EBM, and his GP works out of hours in the NHS. He has received income from appraising treatment recommendations in non-NHS settings and evidence reviews. He is an advisor to Collateral Global, the Sir James Mackenzie Institute for Early Diagnosis at St Andrew's University, and the WHO's International Clinical Trials Registry Platform (ICTRP). He is a member of the Board of Preventing Overdiagnosis. He is also the co-director of the Global Centre for Healthcare and Urbanisation and a Board member of the Speed Trust.